Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1820
- Registration Number
- NCT01856309
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 838
- Registration Number
- NCT01855750
A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Terminated
- Conditions
- First Posted Date
- 2013-05-14
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT01853228
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 581
- Registration Number
- NCT01846611
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 108
- Registration Number
- NCT01840501
A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT01834209
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 56
- Registration Number
- NCT01827982
The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 43
- Registration Number
- NCT01826786
A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 166
- Registration Number
- NCT01823016
A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765
Phase 1
Completed
- Conditions
- First Posted Date
- 2013-03-29
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT01820936
© Copyright 2024. All Rights Reserved by MedPath